Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.23.2
Segment Information (Tables)
6 Months Ended
Jul. 01, 2023
Segment Reporting [Abstract]  
Schedule of Segment Information
The following tables present our segment information for the 13 and 26 weeks ended July 1, 2023 and July 2, 2022 (in $000’s):
Thirteen Weeks Ended Twenty-Six Weeks Ended
July 1, 2023 July 2, 2022 July 1, 2023 July 2, 2022
Revenues
Biotechnology $ —  $ —  $ —  $ — 
Discontinued operations —  10,538  3,795  19,862 
Total Revenues $ —  $ 10,538  $ 3,795  $ 19,862 
Gross profit
Biotechnology $ —  $ —  $ —  $ — 
Discontinued operations —  1,649  (197) 3,502 
Total Gross profit $ —  $ 1,649  $ (197) $ 3,502 
Operating income (loss)
Biotechnology $ (1,060) $ (658) $ (2,159) $ (1,339)
Discontinued operations —  9,639  14,159  9,229 
Total Operating income (loss) $ (1,060) $ 8,981  $ 12,000  $ 7,890 
Depreciation and amortization
Biotechnology $ 362  $ —  $ 726  $
Discontinued operations —  135  96  268 
Total Depreciation and amortization $ 362  $ 135  $ 822  $ 270 
Interest (income) expense, net
Biotechnology $ (365) $ (167) $ (840) $ (165)
Discontinued operations —  807  181  418 
Total Interest expense, net $ (365) $ 640  $ (659) $ 253 
Net income (loss) before income taxes
Biotechnology $ 62  $ (227) $ (827) $ 2,392 
Discontinued operations 9,105  13,976  7,700 
Total Net income before income taxes $ 63  $ 8,878  $ 13,149  $ 10,092